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Background:  The  live  measles  vaccine  has  been  associated  with  lower  non-measles  mortality  and  admis-
sions  in  low-income  countries.  The  live measles–mumps–rubella  vaccine  has  also  been  associated  with
lower  rate  of  admissions  with  any  type  of  infection  in  Danish  children;  the  association  was  strongest  for
admissions  with  lower  respiratory  infections.
Objective: To  examine  whether  measles,  mumps,  and  rubella  (MMR)  vaccination  was  associated  with
reduced  rate of  hospital  contact  related  to  respiratory  syncytial  virus  (RSV)  in  a high-income  country.
Methods:  Nationwide  cohort  study  of laboratory-conﬁrmed  RSV  hospital  contacts  at age  14–23 months
in  all  children  born  in  Denmark  1997–2002  who  had  already  received  the  vaccine  against  diphtheria,
tetanus,  pertussis  (acellular),  polio,  and  Haemophilus  inﬂuenzae  type b  (DTaP-IPV-Hib)  at  the  recom-
mended  ages  of 3, 5, and  12 months.
Results:  The  study  included  888  RSV  hospital  contacts  in  128,588  person  years  of  follow  up (rate  6.8/1000
person  years).  Having  MMR  as  the most  recent  vaccine  was  associated  with  a reduced  rate  of  RSV  hospital
contacts compared  with  having  DTaP-IPV-Hib  as  the  most  recent  vaccine  (Incidence  rate  ratio  (IRR),  0.75;
95% conﬁdence  interval  (CI),  0.63–0.89).  After  adjustment  for potential  confounders  including  exact  age
in  days  the IRR was  0.78 (95%  CI,  0.66–0.93).  The  adjusted  IRR was  0.74  (95%  CI,  0.60–0.92)  in males  and
0.84  (95% CI, 0.66–1.06)  in females  (P  Interaction,  0.42).  There  was  no association  in the  ﬁrst  month  after
MMR  vaccination  (adjusted  IRR,  0.97;  95% CI, 0.76–1.24)  but  the adjusted  IRR  was  0.70 (95%  CI,  0.58–0.85)
from  one  month  after  MMR  vaccination.
Conclusions:  MMR  vaccination  was  associated  with  reduced  rate  of  hospital  contacts  related  to  laboratory-
conﬁrmed  RSV  infection.  Further  research  on the  association  between  MMR  vaccination  and  other
unrelated  pathogens  are  warranted.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Besides the disease-targeted effects, vaccines may  affect mor-
bidity and mortality to unrelated infections by changing the
general level of resistance toward infections, the so-called non-
speciﬁc effects of vaccines [1–3]. In low-income countries, live
Abbreviations: CI, Conﬁdence interval; DTaP-IPV-Hib, Inactivated vaccine
against diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus inﬂuenzae
type b; GP, general practitioner; IRR, incidence rate ratio; MMR, Live vaccine against
measles, mumps, and rubella; OPV, Oral polio vaccine; RSV, Respiratory syncytial
virus.
∗ Corresponding author. Tel.: +45 32 68 36 75.
E-mail address: sgs@ssi.dk (S. Sørup).
vaccines like bacille Calmette–Guérin (BCG) against tubercu-
losis and measles vaccine have beneﬁcial effects on all-cause
child mortality [4–8]. In contrast, inactivated vaccines including
diphtheria–tetanus–pertussis (DTP) vaccine may  increase all-cause
child mortality [9–11]. The nonspeciﬁc effects are often most
marked in females [2,8,10–12]. Most ﬁndings from low-income
countries relate to all-cause mortality. However, nonspeciﬁc effects
of vaccinations on the incidence of infectious diseases and admis-
sion rates have been reported from both low-income [13–17] and
high-income countries [18]. Recently, we found that the rate of
admissions related to infections and particularly lower respiratory
infections was  reduced for Danish children following vaccination
with the live MMR  vaccine against measles, mumps, and rubella
[19].
http://dx.doi.org/10.1016/j.vaccine.2014.07.110
0264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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One of the most common causes of acute lower respiratory tract
infections in infants is respiratory syncytial virus (RSV) [20–22].
Worldwide, an estimated 33.8 million new cases occur each year
leading to 3.4 million hospital admissions of children under 5 years
of age [21]. A study from Guinea-Bissau found that BCG vaccina-
tion reduced the risk of severe RSV infection [16]. The aim of the
present study was to examine the association between MMR  vac-
cine and the rate of hospital contacts resulting from RSV infection
in a high-income setting. In the study period, the Danish recom-
mendations were to administer MMR  (Enders Edmonston, Jeryl
Lynn, and Wistar RA 27/3) at 15 months of age after three doses
of the inactivated vaccine against diphtheria, tetanus, pertussis
(acellular), polio, and Haemophilus inﬂuenzae type b (DTaP-IPV-Hib)
recommended at 3, 5 and 12 months of age (see Supplementary
Fig. 1). The prespeciﬁed hypothesis was that children most recently
vaccinated with MMR  have a lower rate of RSV hospital contact
compared with children vaccinated most recently with the third
dose of DTaP-IPV-Hib (DTaP-IPV-Hib3).
2. Material and methods
The Danish Civil Registration System was established in 1968
and all Danish residents are assigned a unique personal identiﬁca-
tion number [23]. The personal identiﬁcation number is used by all
Danish national registers and was used to link the registers for the
present study.
2.1. Vaccination register
In Denmark, all recommended childhood vaccinations are
administered free-of-charge by the general practitioner (GP). For
the purpose of reimbursement, the GPs report all vaccinations to
the counties and from the counties the data are transferred to
the Danish National Health Service Register [24]. Based on this
information we  created a database of childhood vaccinations. Most
childhood vaccinations were registered in a child’s name, but occa-
sionally childhood vaccinations were registered in a parent’s name
(5.7%), particularly for young infants who only received their own
medical card after they had been named [25]. The recommended
childhood vaccinations were only reimbursed by the counties for
persons below 18 years of age. Childhood vaccinations registered to
an adult can therefore be assumed to have been administered to a
child and we assigned such vaccinations to that adult’s child, which
was closest to the scheduled age of that vaccine. Vaccinations are
only registered on a weekly basis. We  coded date of vaccination as
Wednesday of the registered week of vaccination.
2.2. RSV-database
Information on RSV-related hospital contacts was  obtained from
the Danish nationwide RSV-database, which was established for
research purposes by collection of information from the 18 Danish
laboratories testing for RSV among patients at the Danish hospi-
tals, described in detail elsewhere [26]. The RSV-database covers
the period 1 January 1996 to 1 June 2003 were RSV was  examined
by ELISA or immunoﬂuorescence. During this period, all admitted
children with symptoms consistent with RSV were tested for RSV
to facilitate isolation of RSV cases from other admitted children to
reduce the risk of transmission. In children born in Denmark and
registered in the Danish Civil Registration System, the incidence
rates of hospital contacts with RSV were 25.2, 27.5, 16.0, and 6.8
per 1000 person years among the age groups less than 6 weeks,
6 weeks-6 months, 6–14 months and 14–24 months, respectively.
We only included information on children born on 1 January 1997
and onwards, because the vaccination schedule changed consider-
ably from 1996 to 1997.
2.3. Other register information
The Danish Civil Registration System contains information on
vital status and emigration which we used to deﬁne inclusion date
and follow-up periods [23]. It was also possible to obtain infor-
mation about the composition of each child’s household, and age
and country of birth of the parents. The Danish Medical Birth Reg-
ister contains information about birth weight, mode of delivery,
gestational age, and maternal smoking in pregnancy [27]. The Dan-
ish National Patient Register contains information about discharge
diagnoses [28]; we  used this register to obtain information on other
types of hospital contacts, including accidents and chronic dis-
eases. We  obtained information on household equivalence income
[29], maternal education [30], and public childcare from Statistics
Denmark.
2.4. Design
The study was  designed as a cohort study with retrospective
identiﬁcation of children born in Denmark during 1 January 1997
and 31 March 2002 and who  were alive and living in Denmark at
14 months of age. In the main analysis we  only included children
who had followed the recommended vaccination schedule for the
ﬁrst three vaccination visits by receiving DTaP-IPV-Hib1 before 4
months of age, DTaP-IPV-Hib2 before 6 months of age, and DTaP-
IPV-Hib3 before 13 months of age. The purpose of this selection was
to include children who resemble each other with respect to deter-
minants of vaccination and thereby reduce bias. Further details of
the inclusion are given in Fig. 1. Follow-up was stopped at 2 years
of age since oral polio vaccine (OPV) was  scheduled at 2 years of
age until July 1, 2001 (see Supplementary Fig. 1). The Danish Data
Protection Agency approved the study.
2.5. Statistical methods
To describe determinants of MMR  vaccination, we  estimated the
risk ratios (RRs) of being MMR-vaccinated at 16 months and 2 years
of age according to different covariates using Poisson regression
with robust variance [31].
To estimate incidence-rate-ratios (IRRs) and 95% conﬁdence
intervals (CIs) of RSV hospital contact according to most recent
vaccination we used Cox proportional hazard regression analysis.
Hence, the children changed vaccination status from DTaP-IPV-
Hib3 to MMR  on the date of MMR  vaccination. We included all RSV
hospital contacts, so one child could have several RSV hospital con-
tacts. To minimize the risk that the same episode of RSV infection
counted as two  hospital contacts we deﬁned the duration of one
RSV infection to be 14 days based on the expected maximal period
of shedding [32]. These 14 days were excluded from the count of
person years.
We used age as the underlying timescale of the Cox regression
model and stratiﬁed by date of birth such that cases were only
compared with children born on the same date and at the same
age; hence, we  controlled completely for any potential confound-
ing from age, season, and calendar year. Furthermore, the model
was adjusted for: sex, birth weight in grams (≤2000, 2001–2500,
2501–3000, 3001–3500, 3501–4000, 4001–4500, or >4500), gesta-
tional age (<37 weeks or ≥37 weeks of gestation), caesarean section
(no or yes), number of admissions for any cause between 1 month
of age and date of DTaP-IPV-Hib3 vaccination (none, one, two, or
≥three), admission for any cause from date of DTaP-IPV-Hib3 vac-
cination until 14 months of age (no or yes), maternal age at birth
of the child in years (≤19, 20–24, 25–29, 30–34, 35–39, or ≥40),
S. Sørup et al. / Vaccine 33 (2015) 237–245 239
Fig. 1. Flowchart of the cohort. Abbreviations: RSV respiratory syncytial virus;
DTaP-IPV-Hib vaccination against diphtheria tetanus pertussis (acellular) polio
and Haemophilus inﬂuenzae type b; MMR  vaccination against measles mumps  and
rubella. In the parentheses, number of hospital contacts related to RSV from 14
months and until date of censoring for the children included in the study or
until 2 years of age for the children excluded from the study. a DTaP-IPV or Hib
alone (N = 17,882; 63.0%), not recommended combination of vaccines (N = 5348;
18.8%), fourth dose of DTaP-IPV-Hib (N = 3371; 11.9%), whole cell pertussis vaccine
(N = 1011; 3.6%), OPV (N = 435; 1.5%), booster dose against diphtheria and tetanus
(N  = 252; 0.9%), vaccine against hepatitis B (N = 87; 0.3%), and second dose of MMR
(N  = 10; 0.0%). b Children receiving MMR  before DTaP-IPV-Hib3 were excluded.
parental place of birth (Denmark, Denmark-Foreign, or Foreign),
adult composition of the household (two adults, single parent, or
no parents), other children in the household (no or yes) and the
time-varying variable chronic diseases (no or yes) coded accord-
ing to Kristensen et al., 2012 [33]. In additional analyses described
in the supplementary appendix further adjustment was  made for
maternal smoking in pregnancy, childcare, household income, and
maternal education.
2.5.1. Interactions
Nonspeciﬁc effects of vaccines have previously been found to
interact with sex and vitamin A supplementation [2,3]; other inter-
actions might also be important. For this reason and to assess the
generalizability of the results, we introduced interaction terms
between MMR  and dichotomised forms of the variables adjusted
for in the main analysis. The interaction terms were introduced in
the model one at a time and statistical signiﬁcance was  examined
with Wald test statistics.
2.5.2. Sensitivity
The assumption of proportional hazards between vaccination
groups was  evaluated by Schoenfeld residuals and no violation was
detected. We  examined if the effect of MMR  was immediate by
splitting the time period with MMR  at 30 days after MMR  vaccina-
tion. In addition we  examined for trend in the association according
to time since MMR  vaccination. The stability of the results was
examined by continuing follow-up until 3 years of age. In a sub-
group analysis, we  excluded children who had been admitted to
hospital with RSV before inclusion in the study to limit the poten-
tial effect of immunity to RSV. We  examined the generalizability of
the results by using a cohort which also included the children who
had not received the ﬁrst three doses of DTaP-IPV-Hib on time.
We do not believe that accidents are related to vaccination and
we therefore performed an analysis in which the outcome was acci-
dents registered at emergency room visits to check for possible
registration bias in our data material.
All analyses were performed in Stata 12.
3. Results
A total of 168,511 children were followed until the ﬁrst of the
following events: age 2 years (N = 129,333; 76.8%), 1 June 2003
(N = 25,475; 15.1%), administration of other vaccines than the ﬁrst
MMR (mainly OPV) (N = 13,370; 7.9%), migration (N = 296; 0.2%),
death (N = 31; 0.0%), unknown whereabouts for the Danish author-
ities (N = 4; 0.0%), and uncertainty about vaccinations for twins
(N = 2; 0.0%).
Overall 60.6% were vaccinated with MMR  by 16 months of age
and 91.8% at 2 years of age. There was little variation in the like-
lihood of being MMR-vaccinated, but children of single parents,
younger mothers, and children who  lived together with other chil-
dren were less likely to be MMR-vaccinated, particularly at 16
months of age (Table 1).
In 128,588 person years of follow-up 888 RSV hospital con-
tacts occurred (rate, 6.8/1000 person years); 886 children had one
RSV hospital contact each, while one child had two  RSV hospital
contacts during follow-up. The rate of RSV hospital contact accord-
ing to the vaccination status and age are given in Supplementary
Table 1. The median duration of RSV hospital contacts was  3 days
(inter quartile range, 2–5 days) in both DTaP-IPV-Hib3 and MMR-
vaccinated children.
Compared with children having DTaP-IPV-Hib3 as the most
recent vaccination, having MMR  as the most recent vaccination
was associated with a reduced rate of RSV hospital contacts (IRR,
0.75; 95% CI, 0.63–0.89; Table 2); the adjusted IRR was 0.78 (95%
CI, 0.66–0.93; Table 2). Further adjustment for maternal smoking
in pregnancy, childcare, household income, and maternal educa-
tion did not alter the results (Supplementary Table 3). In males,
the adjusted IRR of RSV hospital contacts for MMR  compared
with DTaP-IPV-Hib3 as the most recent vaccine was  0.74 (95% CI,
0.60–0.92), while the adjusted IRR for females was  0.84 (95% CI,
0.66–1.06; P Interaction, 0.42; Table 3). Also, none of the other
examined interactions were statistically signiﬁcant (Table 3).
The main results of the sensitivity analyses are given here; fur-
ther data is available on request. In the ﬁrst month after MMR
vaccination, the adjusted IRR for MMR  compared with DTaP-IPV-
Hib3 was 0.97 (95% CI, 0.76–1.24) but this changed signiﬁcantly
after one month to an adjusted IRR of 0.70 (95% CI, 0.58–0.85).
There was  a signiﬁcant trend for lower IRRs with longer time since
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Table 1
Distribution of most recent vaccine and risk ratios of being MMR-vaccinated at 16 months and 2 years of age according to background factors.
Characteristics 16 months of age 2 years of age
DTaP-IPV-Hib3% (N)a MMR  % (N)a Adjusted RRb (95%-CI) P valuec DTaP-IPV-Hib3% (N)a MMR  % (N)a Adjusted RRb (95%-CI) P valuec
Sex
Male 39.7% (33,700) 60.3% (51,136) 1 (Ref) .03 8.3% (6486) 91.7% (71,693) 1 (Ref) .10
Female  39.1% (32,328) 60.9% (50,369) 1.01 (1.00–1.02) 8.0% (6147) 92.0% (70,357) 1.00 (1.00–1.01)
Birth  weight, gram
≤2000 40.8% (834) 59.2% (1208) 1.02 (0.98–1.06) .01 8.0% (152) 92.0% (1738) 1.01 (0.99–1.02) .44
2001–2500  39.5% (2027) 60.5% (3107) 1.02 (1.00–1.05) 8.3% (396) 91.7% (4378) 1.00 (0.99–1.01)
2501–3000 38.3% (7978) 61.7% (12,856) 1.02 (1.01–1.04) 8.2% (1568) 91.8% (17,664) 1.00 (1.00–1.01)
3001–3500 39.5% (21,049) 60.5% (32,298) 1 (Ref) 8.2% (4043) 91.8% (45,178) 1 (Ref)
3501–4000 39.4% (22,254) 60.6% (34,200) 1.01 (1.00–1.02) 8.2% (4264) 91.8% (47,878) 1.00 (1.00–1.01)
4001–4500 40.1% (9634) 59.9% (14,377) 1.01 (0.99–1.02) 8.0% (1781) 92.0% (20,395) 1.01 (1.00–1.01)
>4500  39.4% (2252) 60.6% (3,459) 1.03 (1.00–1.05) 8.2% (429) 91.8% (4819) 1.01 (1.00–1.01)
Gestational age, weeks
<37 40.3% (3465) 59.7% (5139) 0.99 (0.96–1.01) .18 7.8% (622) 92.2% (7366) 1.01 (1.00–1.02) .04
≥37 39.4%  (62,563) 60.6% (96,366) 1 (Ref) 8.2% (12,011) 91.8% (134,684) 1 (Ref)
Caesarean section
No 39.5% (56,015) 60.5% (85,886) 1 (Ref) .60 8.2% (10,755) 91.8% (120,192) 1 (Ref) .53
Yes  39.1% (10,013) 60.9% (15,619) 1.00 (0.99–1.01) 7.9% (1878) 92.1% (21,858) 1.00 (1.00–1.01)
Chronic  diseases
No 39.3% (64,154) 60.7% (98,899) 1 (Ref) .03 8.1% (12,242) 91.9% (138,144) 1 (Ref) .40
Yes  41.8% (1874) 58.2% (2606) 0.97 (0.95–1.00) 9.1% (391) 90.9% (3906) 1.00 (0.99–1.01)
Number  of admissions between 1 month of age and date of DTaP-IPV-Hib3 vaccination
None 39.1% (55,540) 60.9% (86,521) 1 (Ref) <.001 8.0% (10,439) 92.0% (120,777) 1 (Ref) <.001
One  40.8% (7858) 59.2% (11,393) 0.98 (0.97–0.99) 9.1% (1617) 90.9% (16,127) 0.99 (0.98–0.99)
Two  42.5% (1747) 57.5% (2367) 0.96 (0.93–0.99) 10.3% (392) 89.7% (3400) 0.98 (0.97–0.99)
Three  or more 41.9% (883) 58.1% (1224) 0.98 (0.94–1.02) 9.6% (185) 90.4% (1746) 0.99 (0.98–1.00)
Admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age
No  39.3% (64,073) 60.7% (98,879) 1 (Ref) <.001 8.1% (12,212) 91.9% (138,262) 1 (Ref) .001
Yes  42.7% (1955) 57.3% (2626) 0.95 (0.92–0.97) 10.0% (421) 90.0% (3788) 0.98 (0.97–0.99)
Maternal age at birth of the child, years
≤19 41.4% (1027) 58.6% (1452) 0.94 (0.91–0.98) <.001 11.9% (277) 88.1% (2043) 0.95 (0.94–0.97) <.001
20–24  37.1% (8509) 62.9% (14,411) 1.01 (1.00–1.02) 8.9% (1858) 91.1% (19,077) 0.98 (0.98–0.99)
25–29  38.1% (24,434) 61.9% (39,708) 1.01 (1.00–1.02) 7.5% (4443) 92.5% (54,593) 1.00 (0.99–1.00)
30–34 40.7% (22,732) 59.3% (33,069) 1 (Ref) 8.0% (4132) 92.0% (47,519) 1 (Ref)
35–39  42.0% (8231) 58.0% (11,357) 0.99 (0.98–1.01) 9.1% (1673) 90.9% (16,635) 0.99 (0.99–1.00)
≥40  42.1% (1095) 57.9% (1508) 0.99 (0.95–1.02) 10.3% (250) 89.7% (2183) 0.98 (0.96–0.99)
Parental place of birth
Denmark 39.2% (55,129) 60.8% (85,372) 1 (Ref) .004 8.2% (10,583) 91.8% (119,060) 1 (Ref) <.001
Denmark and foreign 40.5% (5539) 59.5% (8150) 0.98 (0.96–0.99) 8.4% (1063) 91.6% (11,629) 1.00 (0.99–1.00)
Foreign  40.2% (5360) 59.8% (7983) 1.01 (0.99–1.02) 8.0% (987) 92.0% (11,361) 1.01 (1.01–1.02)
Adult  composition of the household
Two adults 39.2% (61,640) 60.8% (95,795) 1 (Ref) <.001 7.9% (11,517) 92.1% (133,767) 1 (Ref) <.001
Single  parent 43.5% (4293) 56.5% (5573) 0.92 (0.91–0.94) 11.9% (1089) 88.1% (8088) 0.96 (0.95–0.97)
No  parents 40.9% (95) 59.1% (137) 1.03 (0.92–1.15) 12.2% (27) 87.8% (195) 0.98 (0.93–1.03)
Other  children in the household
No 34.9% (27,558) 65.1% (51,327) 1 (Ref) <.001 6.7% (4892) 93.3% (67,715) 1 (Ref) <.001
Yes  43.4% (38,470) 56.6% (50,178) 0.87 (0.86–0.88) 9.4% (7741) 90.6% (74,335) 0.97 (0.96–0.97)
Abbreviations: RR—risk ratio; MMR,  vaccination against measles, mumps, and rubella.
a The number of children do not add to the total number of children in the study, because some children were censored before the speciﬁed age.
b RR of being MMR  vaccinated at the speciﬁed age estimated by Poisson regression with robust variance and adjusted for all variables in the table.
c P values for the test of the association between the speciﬁed variable and vaccination status.
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Table  2
Incidence and incidence-rate-ratios of RSV hospital contact according to vaccination status.
Characteristics RSV hospital contacts per 1000
person years (RSV hospital
contacts/person yearsa)
Unadjusted IRRb (95%-CI) P Valuec Adjusted IRRd (95%-CI) P Valuec
Vaccination status
DTaP-IPV-Hib3 8.9 (320/35,995) 1 (Ref) .001 1 (Ref) .006
MMR  6.1 (568/92,593) 0.75 (0.63–0.89) 0.78 (0.66–0.93)
Abbreviations: RSV—respiratory syncytial virus; IRR—incidence-rate-ratio; DTaP-IPV-Hib3—vaccination with the third dose against diphtheria, tetanus, pertussis (acellular),
polio,  and Haemophilus inﬂuenzae type b; MMR,  vaccination against measles, mumps, and rubella.
a The distribution of person years for each category indicates the demographic features of the included children.
b Cox proportional hazards model with age as underlying time and stratiﬁed by date of birth thereby controlling for age and season.
c P values for the test of the association between the most recent vaccine and RSV hospital contacts.
d Cox proportional hazards model with age as underlying time, stratiﬁed by date of birth and adjusted for sex, birth weight, gestational age, caesarean section, chronic
diseases, number of admissions between 1 month of age and date of DTaP-IPV-Hib3 vaccination, admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age,
maternal age at birth of the child, parental place of birth, adult composition of the household, and other children in the household (the IRR estimates for these variables are
given  in Supplementary Table 2).
MMR  vaccination (Table 4). In the sensitivity analysis in which
the children were followed to 3 years of age, an additional 129
cases of RSV hospital contacts were included and the estimate was
unchanged (adjusted IRR, 0.78; 95% CI, 0.66–0.93). The adjusted
IRR of RSV hospital contact was 0.75 (95% CI, 0.63–0.90) when the
3243 children who had been admitted with RSV before 14 months
of age were excluded. The results were also stable when all chil-
dren were included in the analysis irrespective of whether they
had DTaP-IPV-Hib at the recommended ages (adjusted IRR, 0.79;
95% CI, 0.71–0.89).
There was no statistically signiﬁcant association between MMR
vaccination and emergency room visits resulting from accidents
(adjusted IRR, 1.02; 95% CI, 0.98–1.06).
4. Discussion
As hypothesised children who had received MMR  as their most
recent vaccine had a lower rate of RSV hospital contacts compared
with children who had DTaP-IPV-Hib3 as their most recent vacci-
nation. The association was only apparent from 1 month after MMR
vaccination. The association was similar for females and males and
did not vary signiﬁcantly according to any other background fac-
tors.
The main analyses of the present study included only children
who had been vaccinated on time with DTaP-IPV-Hib to limit the
possibility for confounding by factors related both to delayed vac-
cination and RSV hospital contact. There were too few RSV hospital
contacts among children reversing the sequence of DTaP-IPV-Hib3
and MMR  to perform an analysis in this group. It is important to
emphasize that the statistical model had age in days as the underly-
ing time scale securing elimination of any potential confounding by
age by comparing the incidence of RSV hospital contacts between
children of the exact same age but with different vaccination sta-
tus. Inclusion of a wide range of additional potential confounders
did not change the main estimate appreciably, indicating that con-
founding was limited in the present study.
Since there was no association between MMR  vaccination and
accidents, it seems unlikely that the association between MMR  vac-
cination and RSV hospital contacts can be explained by a bias in
health-seeking behavior.
Vaccinations were registered by GPs to obtain reimbursement;
this provides an economic incentive to report all vaccines [24].
However, there might have been some underreporting of vaccines
[34] and travel vaccines are not reimbursed and therefore not
reported [24], but we believe travel vaccines are limited before
two years of age. Any misclassiﬁcation or underreporting of MMR
vaccinations would bias the estimates toward no association. The
outcome was RSV detected by ELISA or immunoﬂuorescence and
included in the RSV database, which cover 96% of RSV hospital
contacts in Denmark [26]. RSV tests performed by ELISA or
immunoﬂuorescence are not as speciﬁc and sensitive as tests per-
formed by PCR [35] indicating that some misclassiﬁcation is present
in the current study. However, there is no reason to believe that the
sensitivity and speciﬁcity is affected by vaccination status; any mis-
classiﬁcation would bias the results toward no association. There
was a minimum of loss to follow-up because of the high quality of
the Danish population-based registries [23].
Our previous observation of reduction in the rate of all-cause
lower respiratory infections following MMR  vaccination [19] can
now partly be explained by a reduced rate of RSV hospital con-
tacts. However, reduction in hospital contacts related to bacterial
pathogens might also be important; a British self-controlled case-
series study reported the risk of lobar pneumonia to be reduced
0–90 days following MMR  vaccination [36]. In a similarly designed
study of premature children from the US, the risk of wheezing lower
respiratory disease in the ﬁrst 30 days following MMR  vaccination
was reduced compared with 45–90 days after MMR  vaccination
[37]. These studies indicate a short-lived association. However, in
the present study the association between MMR  vaccination and
RSV hospital contacts was only present from 30 days after MMR
vaccination and continued throughout the third year of life.
In contrast to studies from West Africa of measles vaccina-
tion [38,39], we did not ﬁnd any statistically signiﬁcant interaction
between MMR  vaccination and sex. MMR  was  associated with sig-
niﬁcant reduction in RSV hospital contacts in boys but not in girls.
Boys have a higher risk of severe RSV infection [40,41] as also
seen in the present study; therefore there is greater statistical
power to detect differences in boys. Furthermore, MMR  vaccina-
tion may  beneﬁt boys more because of their higher risk of severe
RSV infection. Also, there are numerous differences between high
and low-income settings that might interact with the nonspeciﬁc
and sex-differential effects of vaccinations, including family size,
nutritional status, micronutrient supplementation, sex-differential
access to care, the presence of atopic disease, exposure to infections
in public child care institutions, and genetic differences.
The present study suggests that the MMR  vaccine may  have ben-
eﬁcial nonspeciﬁc effects by reducing the rate of hospital contacts
related to RSV in a high-income setting. Only the most severe cases
of RSV are cared for at the hospital, so the reduction in hospital con-
tacts could be related to a reduction in the severity of RSV infection,
enhanced resistance to RSV infection or both. The ﬁnding contra-
dicts the current perception of vaccines as an intervention with a
disease-speciﬁc effect only. Our observation might be interpreted
as a chance ﬁnding or a ﬁnding resulting from uncontrolled con-
founding of factors related to delay in vaccination and the risk of
RSV hospital contact. However, there were hardly any difference
in characteristics between children who were and were not MMR-
vaccinated at 16 and 24 months of age (Table 1). Furthermore, if
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Table 3
Results for two-way-interactions between vaccination status and dichotomised forms of the variables included in the main analysis.
Characteristics RSV hospital contacts per 1000 person
years (RSV hospital contacts/person years)
Unadjusted IRRa (95%-CI) Adjusted IRRb (95%-CI)
Female
DTaP-IPV-Hib3 7.7 (136/17,637) 1 (Ref) 1 (Ref)
MMR  5.8 (265/45,774) 0.82 (0.65–1.04) 0.84 (0.66–1.06)
Male
DTaP-IPV-Hib3 10.0 (184/18,358) 1 (Ref) 1 (Ref)
MMR  6.5 (303/46,819) 0.70 (0.57–0.87) 0.74 (0.60–0.92)
P  interactionc .28 .42
No  other children in the household
DTaP-IPV-Hib3 8.5 (132/15,580) 1 (Ref) 1 (Ref)
MMR  6.0 (270/44,896) 0.78 (0.61–0.99) 0.82 (0.65–1.04)
Other children in the household
DTaP-IPV-Hib3 9.2 (188/20,415) 1 (Ref) 1 (Ref)
MMR  6.2 (298/47,696) 0.74 (0.60–0.91) 0.76 (0.61–0.94)
P  interactionc .70 .57
No  single parenthood
DTaP-IPV-Hib3 8.7 (294/33,604) 1 (Ref) 1 (Ref)
MMR  5.9 (519/87,445) 0.74 (0.62–0.89) 0.77 (0.64–0.92)
Single parenthood
DTaP-IPV-Hib3 10.9 (26/2391) 1 (Ref) 1 (Ref)
MMR  9.5 (49/5148) 0.96 (0.59–1.57) 1.00 (0.61–1.63)
P  interactionc .30 .30
Only Danish born parents
DTaP-IPV-Hib3 9.7 (294/30,157) 1 (Ref) 1 (Ref)
MMR  6.4 (502/77,870) 0.72 (0.60–0.86) 0.75 (0.63–0.90)
At  least one parent born outside Denmark
DTaP-IPV-Hib3 4.5 (26/5838) 1 (Ref) 1 (Ref)
MMR  4.5 (66/14,723) 1.11 (0.69–1.77) 1.12 (0.70–1.80)
P  interactionc .08 .10
Maternal age <30 years
DTaP-IPV-Hib3 8.9 (168/18,871) 1 (Ref) 1 (Ref)
MMR  6.3 (313/50,078) 0.76 (0.61–0.94) 0.79 (0.64–0.98)
Maternal age ≥30 years
DTaP-IPV-Hib3 8.9 (152/17,124) 1 (Ref) 1 (Ref)
MMR  6.0 (255/42,514) 0.74 (0.59–0.93) 0.77 (0.62–0.97)
P  Interaction c .86 .88
Normal birth weight (>2500 g)
DTaP-IPV-Hib3 8.5 (294/34,484) 1 (Ref) 1 (Ref)
MMR  5.9 (522/88,670) 0.75 (0.63–0.90) 0.79 (0.66–0.94)
Low  birth weight (≤2500 g)
DTaP-IPV-Hib3 17.2 (26/1511) 1 (Ref) 1 (Ref)
MMR  11.7 (46/3923) 0.69 (0.42–1.13) 0.73 (0.44–1.22)
P  interactionc .71 .79
Term (gestational age≥37 weeks)
DTaP-IPV-Hib3 8.6 (293/34,173) 1 (Ref) 1 (Ref)
MMR  5.8 (512/87,914) 0.74 (0.62–0.88) 0.77 (0.64–0.92)
Premature (gestational age<37 weeks)
DTaP-IPV-Hib3 14.8 (27/1822) 1 (Ref) 1 (Ref)
MMR  12.0 (56/4679) 0.87 (0.54–1.40) 0.94 (0.58–1.52)
P  interactionc .53 .42
No  caesarean section
DTaP-IPV-Hib3 8.5 (260/30,582) 1 (Ref) 1 (Ref)
MMR  5.6 (441/78,714) 0.72 (0.60–0.87) 0.75 (0.62–0.90)
Caesarean section
DTaP-IPV-Hib3 11.1 (60/5413) 1 (Ref) 1 (Ref)
MMR  9.2 (127/13,879) 0.88 (0.63–1.22) 0.94 (0.67–1.31)
P  interactionc .25 .21
No  chronic diseases
DTaP-IPV-Hib3 8.6 (301/34,985) 1 (Ref) 1 (Ref)
MMR  5.9 (528/90,110) 0.74 (0.62–0.89) 0.77 (0.65–0.93)
Chronic diseases
DTaP-IPV-Hib3 18.8 (19/1010) 1 (Ref) 1 (Ref)
MMR  16.1 (40/2483) 0.90 (0.51–1.57) 0.94 (0.53–1.67)
P  interactionc .52 .50
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Table  3 (Continued)
Characteristics RSV hospital contacts per 1000 person
years (RSV hospital contacts/person years)
Unadjusted IRRa (95%-CI) Adjusted IRRb (95%-CI)
No admissions between 1 month of age and date of DTaP-IPV-Hib3 vaccination
DTaP-IPV-Hib3 7.4 (225/30,285) 1 (Ref) 1 (Ref)
MMR  4.9 (385/78,784) 0.72 (0.59–0.88) 0.74 (0.60–0.90)
Admissions during 1 month of age and date of DTaP-IPV-Hib3 vaccination
DTaP-IPV-Hib3 16.6 (95/5710) 1 (Ref) 1 (Ref)
MMR  13.3 (183/13,809) 0.86 (0.65–1.12) 0.89 (0.68–1.17)
P  interactionc .28 .23
No  admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age
DTaP-IPV-Hib3 8.5 (298/34,936) 1 (Ref) 1 (Ref)
MMR  5.8 (523/90,193) 0.74 (0.62–0.88) 0.76 (0.64–0.91)
Admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age
DTaP-IPV-Hib3 20.8 (22/1059) 1 (Ref) 1 (Ref)
MMR  18.7 (45/2400) 1.06 (0.62–1.80) 1.12 (0.66–1.92)
P  interactionc .19 .16
Abbreviations: RSV—respiratory syncytial virus; IRR—incidence-rate-ratio; DTaP-IPV-Hib3—vaccination with the third dose against diphtheria, tetanus, pertussis (acellular),
polio,  and Haemophilus inﬂuenzae type b; MMR,  vaccination against measles, mumps, and rubella.
a Cox proportional hazards model with age as underlying time and stratiﬁed by date of birth thereby controlling for age and season.
b Cox proportional hazards model with age as underlying time, stratiﬁed by date of birth and adjusted for sex, birth weight, gestational age, caesarean section, chronic
diseases, number of admissions between 1 month of age and date of DTaP-IPV-Hib3 vaccination, admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age,
maternal age at birth of the child, parental place of birth, adult composition of the household, and other children in the household.
c P value for the interaction term between vaccination status and the speciﬁed variables. This corresponds to testing if the IRR for MMR  varies between categories of the
other  variables; for example, if the IRR for MMR  differs between females and males.
the beneﬁcial effect of MMR  resulted from confounding, the same
beneﬁt should have been observed in the ﬁrst month after vacci-
nation. Several randomized trials from low-income countries have
documented that nonspeciﬁc effects of vaccines are indeed possible
[1]. In one of these trials from Guinea-Bissau [5] measles vaccine
was particularly effective in reducing hospital admissions related
to respiratory infections [17].
Nonspeciﬁc effects of vaccines have often been dismissed as bio-
logically implausible. However, immunological studies have shown
that a pathogen encounter may  alter the subsequent resistance
toward other infections [2,3]. These changes can occur at the level
of the innate immune system; for example, BCG may  enhance
the nonspeciﬁc innate resistance through epigenetic reprogramm-
ing of monocytes [42]. Numerous animal studies have shown that
pathogens can also induce nonspeciﬁc alterations of the adap-
tive immune system, through cross-reacting T-cell epitopes [43].
Notably, measles virus, mumps  virus, and RSV all belong to the
family paramyxoviridae and one study in mice found T-cell cross
reactivity between these viruses [44] and a study in children found
that prior RSV infection was related to higher antibody titres against
measles, mumps, and rubella following vaccination with MMR  [45].
Further studies on the biological mechanisms are clearly needed,
in particular whether antigen-speciﬁc responses or non-speciﬁc
inﬂammatory/innate mechanisms are more important for the pro-
tection we  observed in the present study.
The current WHO  recommendations do not consider nonspe-
ciﬁc effects of vaccines. However, WHO’s Strategic Advisory Group
of Experts has recently recommended further research into non-
speciﬁc effects of vaccines [46]. Ideally, the age schedule for
vaccinations should be evaluated in trials testing both the speciﬁc
effect and the nonspeciﬁc effects on overall morbidity and mortal-
ity. In high-income countries it might reduce the risk of hospital
contacts and reduce health care costs to lower the age of MMR
vaccination or introduce an additional dose of MMR  vaccination
at an earlier age, particularly bearing in mind that the greatest
burden of RSV occurs in children below 12 months of age [21].
If conﬁrmed in further studies in high-income settings, the non-
speciﬁc beneﬁcial effect of MMR  vaccination could be used as an
additional incentive for parents to have their children vaccinated
on time.
In conclusion, the present nationwide cohort study showed that
the rate of RSV hospital contact was reduced in Danish children who
had received MMR  rather than DTaP-IPV-Hib3 as their most recent
vaccination. The ﬁnding has major public health implications. Fur-
ther studies are needed to test this observation and to examine
whether earlier administration of MMR  might be beneﬁcial.
Table 4
Results according to time since MMR  vaccination.
Characteristics RSV hospital contacts per 1000 person
years (RSV hospital contacts/person years)
Unadjusted IRRa (95%-CI) Adjusted IRRb (95%-CI)
Vaccination status
DTaP-IPV-Hib3 8.9 (320/35,989) 1 (Ref) 1 (Ref)
Days  since MMR  vaccination
0–30 8.7 (105/12,107) 0.98 (0.77–1.25) 1.01 (0.79–1.28)
31–90 7.0 (164/23,469) 0.78 (0.62–0.97) 0.82 (0.65–1.03)
91–210 5.6 (239/42,461) 0.62 (0.49–0.79) 0.64 (0.50–0.82)
>210  4.1 (60/14,546) 0.40 (0.27–0.60) 0.43 (0.29–0.64)
P  trend <0.001 <0.001
Abbreviations: RSV—respiratory syncytial virus; IRR—incidence-rate-ratio; DTaP-IPV-Hib3—vaccination with the third dose against diphtheria, tetanus, pertussis (acellular),
polio,  and Haemophilus inﬂuenzae type b; MMR,  vaccination against measles, mumps, and rubella.
a Cox proportional hazards model with age as underlying time and stratiﬁed by date of birth thereby controlling for age and season.
b Cox proportional hazards model with age as underlying time, stratiﬁed by date of birth and adjusted for sex, birth weight, gestational age, caesarean section, chronic
diseases, number of admissions between 1 month of age and date of DTaP-IPV-Hib3 vaccination, admission from date of DTaP-IPV-Hib3 vaccination until 14 months of age,
maternal age at birth of the child, parental place of birth, adult composition of the household, and other children in the household.
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